Table 2. HRs over time for overall survival (OS) by prognostic factors at diagnosis.
| Univariate HR (95% CI) for OS over time | ||||
|---|---|---|---|---|
| Factor | Grouping | 0–2 years | 2–5 years | 5+ years |
| Treatment | CMF, E-CMF | 0.64 (0.46–0.88) | 0.69 (0.55–0.87) | 1.05 (0.78–1.41) |
| Age | ⩽50 years, >50 years old | 1.39 (1.02–1.90) | 1.22 (0.97–1.53) | 1.11 (0.82–1.50) |
| Menopausal status | Pre/peri, post | 1.62 (1.18–2.23) | 1.21 (0.96–1.53) | 0.96 (0.70–1.32) |
| Performance status | 0, 1/2 | 1.26 (0.85–1.86) | 1.39 (1.05–1.85) | 1.07 (0.73–1.57) |
| Surgery | BCS, mastectomy | 2.06 (1.47–2.90) | 1.29 (1.02–1.62) | 1.48 (1.09–2.00) |
| Nodal status | Negative, 1–3 nodes | 1.13 (0.72–1.77) | 1.38 (1.00–1.92) | 1.98 (1.27–3.09) |
| Negative, 4+ nodes | 2.94 (1.91–4.52) | 3.34 (2.41–4.63) | 3.45 (2.17–5.47) | |
| Tumour size | ⩽2 cm, >2 cm | 2.21 (1.54–3.17) | 1.94 (1.51–2.50) | 1.63 (1.20–2.23) |
| VL invasion | Unreported, reported | 1.85 (1.33–2.58) | 1.61 (1.27–2.03) | 1.55 (1.15–2.09) |
| Tumour grade | Well/moderately, poorly differentiated | 2.78 (1.86–4.13) | 1.98 (1.53–2.56) | 0.87 (0.65–1.17) |
| ER status | Positive, negative | 3.30 (2.34–4.66) | 1.41 (1.11–1.79) | 0.69 (0.49–0.96) |
| PgR status | Positive, negative | 5.23 (3.43–7.98) | 1.47 (1.13–1.91) | 0.69 (0.47–1.00) |
| HER2 | Negative, positive | 2.44 (1.72–3.46) | 1.91 (1.44–2.53) | 0.97 (0.62–1.53) |
| EGFR | Negative, positive | 2.01 (1.41–2.85) | 1.13 (0.83–1.53) | 0.86 (0.57–1.30) |
| HER3 | Positive, negative | 1.02 (0.70–1.48) | 1.19 (0.88–1.60) | 0.93 (0.64–1.33) |
| HER1–3 | Negative, positive | 2.28 (1.53–3.41) | 1.21 (0.93–1.58) | 1.03 (0.73–1.47) |
| Ki67 | Low, high | 1.16 (0.82–1.65) | 1.24 (0.95–1.63) | 0.89 (0.63–1.25) |
| Triple negatives | ER positive and HER2 negative, triple negative | 3.48 (2.17–5.57) | 1.50 (1.07–2.12) | 0.46 (0.26–0.81) |
| HER2 | Normal, amplification | 2.32 (1.61–3.33) | 1.91 (1.44–2.53) | 1.13 (0.72–1.77) |
| TOP2A | Amplification, normal | 1.82 (0.85–3.91) | 1.05 (0.68–1.64) | 0.93 (0.52–1.65) |
| TOP2A | Normal, deletion | 2.02 (1.30–3.16) | 1.76 (1.23–2.51) | 0.96 (0.51–1.77) |
| TOP2A | Normal, altered | 1.30 (0.86–1.95) | 1.39 (1.03–1.87) | 1.02 (0.65–1.59) |
| Ch17CEP | Normal, duplication | 1.38 (0.94–2.04) | 1.25 (0.93–1.68) | 0.86 (0.55–1.33) |
Abbreviations: BCS=breast conserving surgery; CI=confidence interval; HR=hazard ratio; CMF=cyclophosphamide, methotrexate and fluorouracil.